GLP-1 Research Peptides: Retatrutide and Tirzepatide Explained

Interest in GLP-1 and multi-agonist peptide research has surged over the past few years, driven largely by high-profile pharmaceutical developments. Here’s what researchers should know about two of the most studied compounds in this class.
Tirzepatide: A Dual-Agonist
Tirzepatide is studied as a dual agonist targeting both GIP and GLP-1 receptor pathways. Research has focused heavily on its role in metabolic pathway studies, including glucose regulation and energy balance models.
Retatrutide: The Triple-Agonist
Retatrutide goes a step further in research models, acting on GIP, GLP-1, and glucagon receptor pathways simultaneously. This triple-agonist mechanism has made it one of the most closely watched compounds in current metabolic peptide research, with ongoing pharmaceutical trials generating significant publication interest.
Why the Research Community Is Watching Closely
Both compounds sit at the center of a rapidly evolving area of pharmaceutical research. For research purposes, this means:
• New published data is emerging frequently
• Batch-to-batch consistency and COA verification matter more than ever
• Sourcing from labs with transparent, published testing is critical given the pace of demand in this category
Sourcing Considerations
Because these compounds are in high demand, the RUO market has seen a wide range of quality — from well-documented, properly tested batches to lower-quality product. When evaluating a source, check for:
• Batch-specific COAs (not a single COA reused across orders)
• Independent lab verification, not just an in-house claim
• Proper cold-chain shipping practices, since these peptides can be sensitive to temperature and light exposure in transit
Bottom Line
Tirzepatide and retatrutide represent some of the most active areas of current peptide research. As with any RUO compound, documentation and lab verification should be the deciding factor in sourcing decisions.